Clinical research on influence of auto or allo-mesenchymal stem cells transplantation on hematopoietic recovery

( views:159, downloads:0 )
Author:
WANG Chun-yan()
TAN Huo(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
HUANG Zhen-qian(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
ZHENG Run-hui(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
LIU Dan(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
LI Hai-ming(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
LUO Xiao-dan(Center of Hematology Oncology, the First Affiliated Hospital of Guangzhou Medical College,Guangzhou 510230, China)
Journal Title:
CANCER RESEARCH AND CLINIC
Issue:
Volume 22, Issue z1, 2010
DOI:
10.3760/cma.j.issn.1006-9801.2010.增.001
Key Word:
Mesenchymal stem cell;Haematopoietic stem cells;Co-transplantation;Hematopoietic recovery

Abstract: Objective To investigate the impact of auto and allogenic mesenchymal stem cells (MSC) transplantation on hematopoietic reconstitution. Methods MSC from auto, donor bone marrow or embryonic tissue were cultured and expanded in vitro in the serum culture system. Five patients received hematopoietic stem cell transplantation (HSCT) were investigated. Case 1 of systemic lupus erythematosus and Case 2 of non-hodgkin' s lymphoma (NHL) received auto MSC transplant before auto-HSCT. Case 3 of paroxysmal nocturnal hemoglobinuria received HLA-identical allogenic MSC transplant before HLA-identical allo-HSCT.Case 4 of chronic myelocytic leukemia and Case 5 of NHL had delayed hematopoietic reconstitution (129th and 78th day, respectively) after allo- and auto-HSCT, respectively, and received MSC from embryonic tissue.Results Case 1, 2 and 3 had no manifested side effects after MSC transplantation combined with HSCT.Neutrophil count of case 1, 2, and 3 were over 0.5 ×109/L at 1st, 10th and 10th day, respectively, platelet count were over 20 ×109/L at 1st, 8th and 33th day, respectively, and agranulocytosis at Ost, 7th and 12th day, respectively. The treatment of embryonic tissue MSC transplant was confirmed to fail for Case 4 and 5.Conclusion The time of MSC transplant has a great impact on hematopoietic reconstitution. MSC transplantation and HSCT performed simultaneously can improve hematopoietic reconstitution. However, the impact of MSC on patients with delayed hematopoietic reconstitution after HSCT needs further study.

  • [1]曹俊燕,乔振华.间充质干细胞预防移植物抗宿主病的研究现状.白血病·淋巴瘤,2006,15:396.
  • [2]Koc ON,Gerson SL,Cooper BW,et al.Rapid hematopoietic recovery after coinfusion of autologous blood stem cells and culture expanded marrow mesenohymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.J Clin 0ncol,2000,18:307-316.
  • [3]Lee ST,Jang JH,Cheong JW,et al.Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.Br J Haematol,2002,118:1128-1131.
  • [4]陆化,李建勇,汪承亚,等.自体骨髓间充质干细胞和外周血造血干细胞移植治疗恶性淋巴瘤.南京医科大学学报,2003,23:63-64.
  • [5]吴冠宇,李建勇,郑敏,等.自体骨髓间充质干细胞联合外周血造血干细胞移植治疗恶性血液病.中华全科医学,2008,8:816-817.
  • [6]夏文杰,许茹,叶欣,等.人骨髓间充质干细胞体外扩增的生物学评估.中国实验血液学杂志,2008,16:639-644.
  • [7]Dazzi F,Horwood NJ.Potential of mesenchymal stem cell therapy.Curr Opin Oncol,2007,19:650-655.
  • [8]Ball LM,Bernardo ME,Roelofs H.Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.Blood,2007,110:2764-2767.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn